budoprutug

Monoclonal antibody

Phase 2topline reported

Evidence outlook

Primary Membranous Nephropathy: topline reported 2026-10-24

The sponsor reported topline results on 2026-10-24 (Initial PrisMN Phase 2 data (interim): mean PLA2R antibody reduction 70% at Week 12; 5 of 13 in immunologic remission). The announcement is listed under Regulatory events.

Also in development:Systemic Lupus Erythematosus · Phase 1/2

Source for the program status

Company guidance: data expected in 2027 (NCT07096843; Climb Bio, Inc., 5 Nov 2026). “Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027” Source ↗

Company guidance: data expected in 2027 (Climb Bio, Inc., 5 Nov 2026). “Budoprutug SC: Future Direction Data in NHPs and healthy volunteers support continued development of SC formulation, with plans to advance to a study in patients to confirm dose and regimen with initial data expected in 2027 NHPs = nonhuman primates, PD = pharmacodynamic, SC = subcutaneous Next Steps Non-Human Primates Data confirmed bioavailability and favorable safety/tolerability Evaluation of SC formulation at full B-cell depleting dose regimen in patients with autoimmune diseases Healthy Volunteers (low dose) Robust PD effects support continued clinical development” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Primary Membranous Nephropathy
Phase 1/2 (3)
Systemic Lupus Erythematosus
NCT06570434 · Tenet Medicines
2025-01 – 2027-04 · Systemic Lupus Erythematosus, SLE, B Cells
What this study did
Other / comorbidity
NCT07043946 · Climb Bio, Inc.
2025-06-30 – 2028-08 · Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19
What this study did
Phase 1 (2)
Systemic Lupus Erythematosus
Other / comorbidity
NCT07090655 · Climb Bio, Inc.
2025-08-11 – 2026-04-07 · Healthy Volunteers
What this study did

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, 3 of them ahead of this one.

This drug's own stage for Primary Membranous Nephropathy: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Budoprutug: this drugPhase 2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Obinutuzumab Beta (Bejescin)Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 2/3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ALXN1920Phase 2Protein / enzyme therapeuticComplement factor Hnot yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow budoprutug to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
April 2027 (1)
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-04 · NCT07011043 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1/2Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19Recruiting
Est. primary completion 2027-08 · NCT07043946 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-09 · NCT07564596 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Primary Membranous NephropathyRecruiting
Est. primary completion 2027-10 · NCT07096843 · CT.gov ↗

Company guidance: data expected in 2027 (Climb Bio, Inc., 5 Nov 2026). “Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 October 2026Topline resultInitial PrisMN Phase 2 data (interim): mean PLA2R antibody reduction 70% at Week 12; 5 of 13 in immunologic remission
US · Climb Bio, Inc. · Source ↗
5 May 2026Topline resultPhase 1 topline of subcutaneous budoprutug in healthy volunteers
Climb Bio, Inc. · Source ↗